Chronic inflammatory demyelinating polyneuropathy
The global Chronic inflammatory demyelinating polyneuropathy market size reached US$ 2.02 Billion in 2024 and is expected to reach US$ 5.07 Billion by 2033, growing at a CAGR of 9.7% during the forecast period 2025-2033.
The chronic inflammatory demyelinating polyneuropathy market is driven by a rapidly aging population with higher neuropathy prevalence, improved diagnostic capabilities, expanding access to immunoglobulin and biologic therapies, supportive reimbursement and rare-disease policies, increasing specialist neuromuscular centers, and active clinical research collaborations that accelerate treatment adoption and long-term disease management nationwide.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/chronic-inflammatory-demyelinating-polyneuropathy-market?pratik
Japan: Key Industry Developments
1. VYVDURA – expanded CIDP approval & treatment access in Japan
VYVDURA (efgartigimod alfa and hyaluronidase‐qvfc), marketed in Japan as, has been approved for adult CIDP treatment, representing one of the first innovative FcRn‐blocking therapies in the Japanese CIDP landscape and providing a weekly subcutaneous administration option. Approval and clinical use commenced following regulatory action in previous years, and in 2025 the dosing period restriction was formally removed, easing long‐term treatment flexibility for CIDP patients.
2. Riliprubart – orphan drug designation for CIDP in Japan (development stage)
In June 2025, the Japanese Ministry of Health, Labour and Welfare granted orphan drug designation to riliprubart (SAR445088), a monoclonal antibody targeting activated C1s in the complement pathway, for the treatment of CIDP. This designation supports ongoing Phase 3 clinical trials and underscores progress toward a potential first‐in‐class complement‐targeted therapy in Japan.
Market Segmentation Analysis:
Segmentation by treatment type highlights the diversity of therapeutic approaches utilized in Japan’s CIDP market. Conventional therapies such as intravenous immunoglobulin (IVIG), corticosteroids, and plasmapheresis remain foundational, with IVIG therapies widely adopted due to their clinical effectiveness and suitability as first‐line options. Other segments include emerging immunotherapies and supportive care like physiotherapy, reflecting a shift toward personalized and multimodal treatment regimens in response to varied patient needs.
From a diagnostic standpoint, the market segmentation covers multiple diagnostic tools that inform treatment decisions, including electrodiagnostic testing, EMG, cerebrospinal fluid analysis, and laboratory panels. This diagnostic segmentation underscores Japan’s emphasis on precise subtype differentiation-between typical and atypical CIDP variants-as part of efforts to optimize therapeutic outcomes.
Route of administration is another important segment in the Japanese market, with injectable and intravenous forms dominating, given the nature of most approved CIDP therapies (e.g., IVIG and biologics). Emerging subcutaneous formulations are also gaining interest for convenience and potential home‐based administration models.
In terms of end‐user segmentation, hospitals and specialty neurology clinics represent the primary revenue sources due to centralized treatment delivery, comprehensive care infrastructure, and reimbursement frameworks that support complex CIDP care. Pharmacies and outpatient clinics further contribute to distribution and patient access segments, particularly as treatment paradigms evolve.
Key Players:
Bio Products Laboratory Ltd, Momenta Pharmaceuticals, Grifols, Baxter, Kedrion S.p.A, Octapharma, Shire, Mitsubishi Tanabe Pharma Corporation,CSL Behring, Teijin Pharma Limited and Pfizer, Inc.
Purchase this report before year-end and unlock an exclusive 30% discount:https://www.datamintelligence.com/buy-now-page?report=chronic-inflammatory-demyelinating-polyneuropathy-market?pratik (Purchase 2 or more Reports and get 50% Discount)
Growth Drivers:
Rising Aging Population: Japan has a high elderly population, increasing CIDP prevalence.
Improved Diagnosis: Advanced diagnostic tools and greater physician awareness support early detection.
Growing Healthcare Spending: Government initiatives and insurance coverage improve patient access to treatment.
Advancements in Therapies: Introduction of new immunotherapies and biologics fuels market growth.
Patient Awareness Programs: Campaigns and advocacy groups enhance recognition and treatment uptake.
Supportive Regulatory Environment: Streamlined approval pathways for innovative therapies encourage market expansion.
Regional Market Dynamics –
North America – 40% Share
North America leads with 40%, driven by high awareness of autoimmune disorders, established healthcare infrastructure, early adoption of advanced therapies, and strong R&D investment in neurological treatments.
Europe – 28% Share
Europe holds 28%, supported by well-established healthcare systems, rising prevalence of CIDP, favorable reimbursement policies, and ongoing clinical trials in Germany, France, the U.K., and Italy.
Asia-Pacific – 22% Share
Asia-Pacific accounts for 22%, fueled by growing awareness, increasing diagnosis rates, improving healthcare access, and government initiatives in Japan, China, India, and South Korea to support neurological care.
South America – 5% Share
South America holds 5%, supported by gradual awareness of CIDP, improving healthcare facilities, and limited availability of advanced therapies in Brazil, Argentina, and neighboring countries.
Speak to Our Analyst and Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/chronic-inflammatory-demyelinating-polyneuropathy-market?pratik
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?pratik
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us –
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us –
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele
This release was published on openPR.
AloJapan.com